Central demyelinating disorders and hepatitis B vaccination:: a risk-benefit approach for pre-adolescent vaccination in France

被引：15

作者：

Lévy-Bruhl, D ^{[1
]}

Desenclos, JC ^{[1
]}

Rebière, I ^{[1
]}

Drucker, J ^{[1
]}

机构：

[1] Inst Veille Sanitaire, Dept Maladies Infect, F-24415 St Maurice, France

来源：

VACCINE | 2002年 / 20卷 / 16期

关键词：

hepatitis B vaccination; risk-benefit analysis; pre-adolescent; central demyelinating disease;

D O I：

10.1016/S0264-410X(02)00053-1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The objective of the study was to provide immunization policy decision makers with a risk-benefit analysis for pre-adolescents vaccination. for various scenarios regarding the existence and the strength of an association between hepatitis B vaccination and the occurrence of first episode of central demyelinating (FECD) disease. The risks were assessed as the attributable risks of FECD for various time intervals between vaccination and onset of FECD and the benefits as the number of acute fulminant hepatitis B and cirrhosis prevented in a vaccinated annual cohort. Even in the worst-case considered, the number of complications prevented by the vaccination outweighs quantitatively the potential risks. Even if both sides of the balance are of different medical and sociological nature, this result is in favor of reinforcing the pre-adolescent vaccination strategy in France. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：2065 / 2071

页数：7

共 20 条

[1] THE CHANGING EPIDEMIOLOGY OF HEPATITIS-B IN THE UNITED-STATES - NEED FOR ALTERNATIVE VACCINATION STRATEGIES [J].

ALTER, MJ ;

HADLER, SC ;

MARGOLIS, HS ;

ALEXANDER, WJ ;

HU, PY ;

JUDSON, FN ;

MARES, A ;

MILLER, JK ;

MOYER, LA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (09) :1218-1222

[2] Hepatitis B vaccination and the risk of multiple sclerosis [J].

Ascherio, A ;

Zhang, SM ;

Hernán, MA ;

Olek, MJ ;

Coplan, PM ;

Brodovicz, K ;

Walker, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :327-332

[3]

BALTAGI J, 1997, ACTUALITE DOSSIER SA, V20, P7

[4]

Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6

[5]

*CDCP, 2000, EP PREV VACC PREV DI

[6]

*COM CONS NAT IMM, 1991, RHMC, V17, P165

[7] Vaccinations and the risk of relapse in multiple sclerosis [J].

Confavreux, C ;

Suissa, S ;

Saddier, P ;

Bourdés, V ;

Vukusic, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :319-326

[8]

DESTRASBOURGALS.CR, 1999, NAT PHARM COMM 1 JUN

[9]

*DIR GEN SANT, 1995, B EPIDEMIOLOGIQUE HE, V2, P5

[10]

*LAB SMITHKL BEECH, 1998, OBS VACC CONTR HEP B

← 1 2 →